The Library
Platelet-rich therapy in the treatment of patients with hip fractures: a single centre, parallel group, participant-blinded, randomised controlled trial
Tools
Tools
Tools
Griffin, Xavier L., Achten, Juul, Parsons, Nicholas R. and Costa, Matthew L. (2013) Platelet-rich therapy in the treatment of patients with hip fractures: a single centre, parallel group, participant-blinded, randomised controlled trial. BMJ Open, Volume 3 (Number 6). Article number e002583. doi:10.1136/bmjopen-2013-002583
|
Text
WRAP_Griffin_BMJ Open-2013-Griffin-.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. Download (635Kb) | Preview |
Official URL: http://dx.doi.org/10.1136/bmjopen-2013-002583
Abstract
Objective: To quantify and draw inferences on the clinical effectiveness of platelet-rich therapy in the management of patients with a typical osteoporotic fracture of the hip.
Design: Single centre, parallel group, participant-blinded, randomised controlled trial.
Setting: UK Major Trauma Centre.
Participants: 200 of 315 eligible patients aged 65 years and over with any type of intracapsular fracture of the proximal femur. Patients were excluded if their fracture precluded internal fixation.
Interventions: Participants underwent internal fixation of the fracture with cannulated screws and were randomly allocated to receive an injection of platelet-rich plasma into the fracture site or not.
Main outcome measures: Failure of fixation within 12 months, defined as any revision surgery.
Results: Primary outcome data were available for 82 of 101 and 78 of 99 participants allocated to test and control groups, respectively; the remainder died prior to final follow-up. There was an absolute risk reduction of 5.6% (95% CI −10.6% to 21.8%) favouring treatment with platelet-rich therapy (χ2 test, p=0.569). An adjusted effect estimate from a logistic regression model was similar (OR=0.71, 95% CI 0.36 to 1.40, z test; p=0.325). There were no significant differences in any of the secondary outcome measures excepting length of stay favouring treatment with platelet-rich therapy (median difference 8 days, Mann-Whitney U test; p=0.03). The number and distribution of adverse events were similar. Estimated cumulative incidence functions for the competing events of death and revision demonstrated no evidence of a significant treatment effect (HR 0.895, 95% CI 0.533 to 1.504; p=0.680 in favour of platelet-rich therapy).
Conclusions: No evidence of a difference in the risk of revision surgery within 1 year in participants treated with platelet-rich therapy compared with those not treated. However, we cannot definitively exclude a clinically meaningful difference.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > R Medicine (General) R Medicine > RM Therapeutics. Pharmacology |
||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School Faculty of Medicine > Warwick Medical School > Health Sciences > Clinical Trials Unit |
||||
| Library of Congress Subject Headings (LCSH): | Hip joint -- Diseases , Hip joint -- Surgery, Clinical medicine, Blood platelets, Orthopedics | ||||
| Journal or Publication Title: | BMJ Open | ||||
| Publisher: | BMJ | ||||
| ISSN: | 2044-6055 | ||||
| Official Date: | 25 June 2013 | ||||
| Dates: |
|
||||
| Volume: | Volume 3 | ||||
| Number: | Number 6 | ||||
| Page Range: | Article number e002583 | ||||
| DOI: | 10.1136/bmjopen-2013-002583 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Open Access | ||||
| Funder: | BUPA Foundation, Orthopaedic Research UK |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
